XPO1 inhibitors are approved by the FDA for multiple myeloma and demonstrated an acceptable toxicity profile, but only modest clinical activity as monotherapy in a phase I study of adult all-comers with R/R AML (Garzon et al., 2017). The gene discussed is XPO1; the disease is acute myeloid leukemia.